Conformational Changes of Blood ACE in Chronic Uremia

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Petrov, Maxim N ^a   Shilo, Valery Y ^b   Tarasov, Alexandr V ^a   Schwartz, David E ^c   Garcia, Joe G N ^c   Kost, Olga A ^a   Danilov, Sergei M ^c,d  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; LISINOPRIL; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; UREMIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; ENALAPRILAT; EPITOPES; HUMANS; IMMUNOPRECIPITATION; KIDNEY FAILURE, CHRONIC; MODELS, MOLECULAR; PEPTIDYL-DIPEPTIDASE A; PROTEIN BINDING; PROTEIN CONFORMATION; TEPROTIDE; UREMIA;

EID: 84869224853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049290     Document Type: Article

References (87)

1. Ehlers MWR, Riordan JF, (1989) Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 8: 5311-5318.
2. Bernstein KE, Xiao HD, Frenzel K, Li P, Shen XZ, et al. (2005) Six truisms concerning ACE and the renin-angiotensin system educed from the genetic analysis of mice. Circ Res 96: 1135-1144.
3. Sturrock ED, Anthony CS, Danilov SM (2012) Peptidyl-dipeptidase A/Angiotensin I-converting enzyme. In: Editors-in-Chief: Neil D. Rawlings, Guy Salvesen, Handbook of Proteolytic Enzymes, 3rd Edition, Academic Press, Oxford (in press).
4. Caldwell PR, Seegal BC, Hsu KC, Das H, Soffer RL, (1976) Angiotensin-converting enzyme: vascular endothelial localization. Science 191: 1050-1051.
5. Ryan US, Ryan JW, Whitaker C, Chiu A, (1976) Localization of angiotensin converting enzyme (kininase II). II. Immunocytochemistry and immunofluorescence. Tissue Cell 8: 124-145.
6. Balyasnikova IV, Danilov SM, Muzykantov VR, Fisher AB, (1998) Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells. In Vitro Dev Biol Anim 34: 545-554.
7. Metzger R, Franke FF, Bohle RM, Alhenc-Gelas F, Danilov SM, (2011) Heterogeneous distribution of Angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessels, organs and species specificity. Microvasc Res 82: 206-215.
8. Defendini R, Zimmerman EA, Weare JA, Alhenc-Gelas F, Erdos EG, (1983) Angiotensin-converting enzyme in epithelial and neuroepithelial cells. Neuroendocrinology 37: 32-40.
9. Bruneval P, Hinglais N, Alhenc-Gelas F, Tricottet V, Corvol P, et al. (1986) Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization. Histochemistry 85: 73-80.
10. Hooper NM, Turner AJ, (1987) Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin-converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. Biochem J 241: 625-633.
11. Silverstein E, Friedland J, Setton C, (1978) Angiotensin-converting enzyme in macrophages and Freund's adjuvant granuloma. Isr J Med Sci 14: 314-318.
12. Danilov SM, Sadovnikova E, Scharenbourg N, Balysnikova IV, Svinareva DA, et al. (2003) Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocytes-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hem 31: 1301-1309.
13. Danilov SM, Franke FE, Erdos EG (1997) Angiotensin-Converting Enzyme (CD143). In: Leucocyte Typing VI: White Cell differentiation Antigens. (Kishimoto T., et al., Eds.) Garland Publishing Inc.New York. 746-749.
14. Franke FE, Metzger R, Bohle RM, Kerkman L, Alhenc-Gelas F, et al. (1997) Angiotensin I-Converting Enzyme (CD 143) on endothelial cells in normal and in pathological conditions. In: Leucocyte Typing VI: White Cell Differentiation Antigens. (Kishimoto T., et al., Eds.) Garland Publishing Inc. New York. 749-751.
15. Beneteau-Burnat B, Baudin B, (1991) Angiotensin-converting enzyme: clinical applications and laboratory investigation in serum and other biological fluids. Crit Rev Clin Lab Sci 28: 337-356.
16. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM, Corvol P, (1991) Distribution of plasma angiotensin I-converting enzyme levels in healthy men: Relationship to environmental and hormonal parameters. J Lab Clin Med 117: 33-39.
17. Lieberman J, (1975) Elevation of serum angiotensin-converting enzyme level in sarcoidosis. Am J Med 59: 365-372.
18. Lieberman J, Beutler E, (1976) Elevation of angiotensin-converting enzyme in Gaucher's disease. N Engl J Med 294: 1442-1444.
19. Silverstein E, Friedland J, Lyons HA, Gourin A, (1976) Elevation of angiotensin-converting enzyme in granulomatous lymph nodes and serum in sarcoidosis: clinical and possible pathological significance. Ann NY Acad Sci 278: 498-513.
20. Romer FK (1984) Clinical and biochemical aspects of sarcoidosis. With special reference to angiotensin-converting enzyme (ACE). Acta Med Scand Suppl 690: 3-96.
21. Patel R, Ansari A, (1979) Serum angiotensin converting enzyme activity in patients with chronic renal failure on long term hemodialysis. Clin Chem Acta 92: 491-495.
22. Silverstein E, Brunswick J, Rao TK, Friedland J, (1984) Increased serum angiotensin-converting enzyme in chronic renal disease. Nephron 37: 206-210.
23. Dux S, Aron N, Boner G, Carmel A, Yaron A, et al. (1984) Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension. Isr J Med Sci 20: 1138-1142.
24. Ching SF, Hayes LW, Slakey LL, (1983) Angiotensin-converting enzyme in cultured endothelial cells. Synthesis, degradation and transfer to culture medium. Arteriosclerosis 3: 581-588.
25. Parkin ET, Turner AJ, Hooper NM, (2004) Secretase-mediated cell surface shedding of the angiotensin-converting enzyme. Protein Pept Lett 11: 423-432.
26. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, et al. (1988) Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 85: 9386-9390.
27. Naperova IA, Balyasnikova IV, Schwartz DE, Watermeyer J, Sturrock DE, et al. (2008) Mapping of conformational mAb epitopes to the C domain of human angiotensin I-converting enzyme (ACE). J Proteome Res 7: 3396-3411.
28. Chen HL, Lunsdorf H, Hecht HJ, Tsai H, (2010) Porcine pulmonary angiotensin I-converting enzyme- Biochemical characterization and spatial arrangement of the N- and C-domains by three-dimensional electron-microscopic reconstruction. Micron 41: 674-685.
29. Danilov SM, Gordon K, Nesterovitch AB, Chen Z, Castellon M, et al. (2011) An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding. PLoS One 6: e25952.
30. Natesh R, Schwager SL, Sturrock ED, Acharya KR, (2003) Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421: 551-554.
31. Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, Acharya KR, (2006) Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol 357: 964-974.
32. Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F, et al. (1994) Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. J Biol Chem 269: 26806-26814.
33. Balyasnikova IV, Metzger R, Visintine DJ, Dimasius V, Sun ZL, et al. (2005) A new set of monoclonal antibodies to rat angiotensin I-converting enzyme (ACE) for the lung endothelial targeting. Pulm Pharm Ther 18: 251-267.
34. Balyasnikova IV, Metzger R, Sun ZL, Berestetskaya YV, Albrecht RFII, et al. (2005) Development and characterization of rat monoclonal antibodies to denatured mouse angiotensin-converting enzyme. Tissue Antigens 65: 240-251.
35. Balyasnikova IV, Sun ZL, Metzger R, Taylor PR, Vicini E, et al. (2006) Monoclonal antibodies to native mouse angiotensin-converting enzyme (CD143): ACE expression; quantification; lung endothelial cell targeting and gene delivery. Tissue Antigens 67: 10-29.
36. Balyasnikova IV, Metzger R, Franke FE, Towbin H, Gordon K, et al. (2008) Epitope mapping of mAbs to denatured human testicular ACE. Tissue Antigens 72: 354-368.
37. Danilov S, Savoie F, Lenoir B, Jeunemaitre X, Azizi M, et al. (1996) Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. J Hypertens 14: 719-727.
38. Nikolaeva MA, Balyasnikova IV, Alexinskaya MA, Metzger R, Franke FE, et al. (2006) Testicular isoform of angiotensin I-converting enzyme (ACE; CD143) on the surface of human spermatozoa: revelation and quantification using monoclonal antibodies. Am J Reprod Immunol 55: 54-68.
39. Balyasnikova IV, Karran EH, Albrecht RF, Danilov SM, (2002) Epitope-specific antibody-induced cleavage of angiotensin-converting enzyme from the cell surface. Biochem J 362: 585-595.
40. Kost OA, Balyasnikova IV, Chemodanova EE, Nikolskaya II, Albrecht RF, et al. (2003) Epitope-dependent blocking of the angiotensin-converting enzyme dimerization by monoclonal antibodies to the N-terminal domain of ACE: possible link of ACE dimerization and shedding from the cell surface. Biochemistry 42: 6965-6976.
41. Balyasnikova IV, Woodman ZL, Albrecht RFII, Natesh R, Acharya KR, et al. (2005) Localization of an N domain region of angiotensin-converting enzyme involved in the regulation of ectodomain shedding using monoclonal antibodies. J Proteome Res 4: 258-267.
42. Skirgello OE, Balyasnikova IV, Binevski PV, Sun ZL, Baskin II, et al. (2006) Inhibitory antibodies to human angiotensin-converting enzyme: fine epitope mapping and mechanism of action. Biochemistry 45: 4831-4847.
43. Balyasnikova IV, Skirgello OE, Binevski PV, Nesterovitch AB, Albrecht RFII, et al. (2007) Monoclonal antibodies 1G12 and 6A12 to the N-domain of human angiotensin-converting enzyme: fine epitope mapping and antibody-based method for revelation and quantification of ACE inhibitors in the human blood. J Proteome Res 6: 1580-1594.
44. Danilov SM, Watermeyer JM, Balyasnikova IB, Gordon K, Kugaevskaya EV, et al. (2007) Fine epitope mapping of mAb 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme. Biochemistry 46: 9019-9031.
45. Gordon K, Balyasnikova IV, Nesterovitch AB, Schwartz DE, Sturrock ED, et al. (2010) Fine epitope mapping of monoclonal antibodies 9B9 and 3G8, to the N domain of human angiotensin I-converting enzyme (ACE) defines a region involved in regulating ACE dimerization and shedding. Tissue Antigens 75: 136-150.
46. Danilov SM, Deinum J, Balyasnikova IV, Sun ZL, Kramers C, et al. (2005) Detection of mutated angiotensin I-converting enzyme by serum/plasma analysis using a pair of monoclonal antibodies. Clin Chem 51: 1040-1043.
47. Nesterovitch AB, Hogarth K, Adarichev VA, Vinokour EI, Schwartz D, et al. (2009) Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. PLoS One 4: (12) e8282.
48. Danilov SM, Kalinin S, Chen Z, Vinokour EI, Nesterovitch AB, et al. (2010) Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C domain. PLoS One 5: e10438.
49. Danilov SM, Balyasnikova IB, Danilova AS, Naperova IA, Arablinskaya E, et al. (2010) Conformational fingerprinting of the angiotensin-converting enzyme (ACE): Application in sarcoidosis. J. Proteome Res 9: 5782-5793.
50. Balyasnikova IV, Sun ZL, Berestetskaya YV, Albrecht RAII, Sturrock ED, et al. (2005) Monoclonal antibodies 1B3 and 5C8 as probes for monitoring the nativity of C-terminal end of soluble angiotensin-converting enzyme (ACE). Hybridoma 24: 14-26.
51. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, et al. (2003) Review on uremic toxins: classification; concentration; and interindividual variability. Kidney Int. 63: 1934-1943.
52. Piquilloud Y, Reinharz A, Roth M, (1970) Studies on the angiotensin-converting enzyme with different substrates. Biochim Biophys Acta 206: 136-142.
53. Friedland J, Silverstein E, (1976) A sensitive fluorometric assay for serum angiotensin-converting enzyme. Am J Pathol 66: 416-424.
54. Danilov SM, Balyasnikova IV, Albrecht RFI, Kost OA, (2008) Simultaneous determination of ACE activity with two substrates provides information on the status of somatic ACE and allows detection of inhibitors in human blood. J Cardiovasc Pharmacol 52: 90-103.
55. Balyasnikova IV, Gavriljuk VD, McDonald TD, Berkowitz R, Miletich DJ, et al. (1999) Antibody-mediated lung endothelium targeting: In vitro model using a cell line expressing angiotensin-converting enzyme. Tumor Targeting 4: 70-83.
56. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, et al. (1991) Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 266: 5540-5546.
57. Balyasnikova IV, Metzger R, Franke FE, Danilov SM, (2003) Monoclonal antibodies to denatured human ACE (CD 143), broad species specificity, reactivity on paraffin sections, and detection of subtle conformational changes in the C-terminal domain of ACE. Tissue Antigens 61: 49-62.
58. Ehlers MRW, Chen YN, Riordan JF, (1991) Spontaneous solubilization of membrane-bound human testis angiotensin-converting enzyme expressed in Chinese hamster ovary cells. Proc Natl Acad Sci USA 88: 1009-1013.
59. Jokubaitis VJ, Sinka L, Driessen R, Whitty G, Haylock DN, et al. (2008) Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic; fetal and adult hematopoietic tissues. Blood 111: 4055-4063.
60. Sturrock ED, Yu XC, Wu Z, Biemann K, Riordan J, (1996) Assignment of free-and disulfide-bonded cysteine residues in testis angiotensin-converting enzyme: functional implications. Biochemistry 35: 9560-9566.
61. Jones DP, Carlson JL, Samiec PS, Sternberg P, Mody VC, et al. (1998) Glutathione measurement in human plasma. Evaluation of sample collection; storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta 275: 175-184.
62. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R, (2004) Interference of plasmatic reduced glutathione and hemolysis on glutathione disulfide levels in human blood. Free Rad Res 10: 1101-1106.
63. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM, (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538.
64. Ward RA, McLeish KR, (2003) Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 27: 230-236.
65. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP, (2005) Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis- associated inflammation. Hemodial Int 9: 37-46.
66. Lucchi L, Bargamini S, Iannone A, Perrone S, Stipo L, et al. (2005) Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments. Artif Organs 29: 67-72.
67. Stepniewska J, Dolegowska B, Ciechanowski K, Kwiatkowska E, Millo B, et al. (2006) Erythrocyte antioxidant defense system in patients with chronic renal failure according to the hemodialysis conditions. Arch Med Res 37: 353-359.
68. Herzog CE, Ma JZ, Collins AJ, (2002) Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 105: 1336-1341.
69. Gendlin GE, Shilo VYu, Tomilina NA, Storogakov GI, Borisovskaya SV, et al. (2009) Left ventricular myocardial hypertrophy and its prognostic role at chronic kidney disease. Clinical Nephrology (Russian) 1: 22-28.
70. Suzuki H, (2009) Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis. Ther Adv Cardiovasc Dis 3: 397-405.
71. Inrig JK, (2010) Antihypertensive agents in hemodialisys patients. Semin Dial 23: 290-297.
72. Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, et al. (2006) Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 70: 1318-1324.
73. Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, et al. (2011) Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J 162: 324-330.
74. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, (2002) ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40: 1023-1029.
75. McCullough PA, Sandberg KR, Yee J, Hudson MP, (2002) Mortality benefit of angiotensin-converting enzyme inhibitor after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 3: 188-191.
76. Menard J, Patchett AA, (2001) Angiotensin-converting enzyme inhibitors. Adv Protein Chem 56: 13-75.
77. Silva ACS, Diniz JSS, Pereira RM, Pinheiro SVB, Santos RAS, (2006) Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1-7) in end-stage renal disease. Ped Res 60: 734-739.
78. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM, (2005) Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? - a systematic review. Curr Control Trials Cardiovasc Med 6: 16.
79. Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM, (2007) ACE pheno-typing as a first step toward personalized medicine for ACE inhibitors. Why does ACE geno-typing not predict the therapeutic efficacy of ACE inhibition? Pharm Ther 113: 607-618.
80. Kramer AB, Laverman GD, van Goor H, Navis G, (2003) Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephritic rats are predicted by pretreatment renal damage. J Pathol 201: 160-167.
81. Windt WA, van Dokkum RPE, Kluppel CA, Jeronimus-Stratingh CM, Hut F, et al. (2008) Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to phar-macodynamic and kinetic factors in 5/6 nephrectomized rats. Eur J Pharmacol 580: 231-240.
82. Ryan JW, Martin LC, Chung A, Pena GA (1979) Mammalian inhibitors of angiotensin-converting enzyme (kininase II). In Advances in Experimental Medicine and Biology. KininsII; 120B; (Fuji S., Moriya M., Suzuki T., Eds.). Plenum: New York, 599-606.
83. Hazato T, Kase R, (1986) Isolation of angiotensin-converting enzyme inhibitor from porcine plasma. Biochem Biophys Res Communs 139: 52-55.
84. Lieberman J, Sastre A, (1986) An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis. Chest 90: 869-875.
85. Ikemoto F, Song GB, Tominaga M, Yamamoto K, (1989) Endogenous inhibitor of angio-tensin-converting enzyme in the rat heart. Biochem Biophys Res Communs 159: 1093-1099.
86. Brecher AS, Thevananter S, Wilson S, (1996) Observation of high and low MW inhibitors of angiotensin converting enzyme in rat lung. Arch Int Pharmacodyn Ther 331: 301-312.
87. Thevananter S, Brecher AS, (1999) Isolation of angiotensin converting enzyme (ACE) binding protein from human serum with an ACE affinity column. Can J Physiol Pharmacol 77: 216-223.